Efficacy and Safety of Dapagliflozin As Monotherapy in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Jul 27

PMID 31348290

Citations 15

Authors

Miao Feng

Haihong Lv

Xia Xu

Jue Wang

Wenyi Lyu

Songbo Fu

Affiliations

Soon will be listed here.

Abstract

Background: Dapagliflozin, a novel inhibitor of sodium-glucose cotransporter-2 (SGLT-2), lowers blood glucose level by specifically inhibiting the activity of SGLT-2. Previous studies showed efficacy and safety of dapagliflozin combined with other antihyperglycemic agents in type 2 diabetes (T2DM), however, there are few studies for dapagliflozin as monotherapy. The aim of this study was to assess the efficacy and safety of dapagliflozin as a monotherapy in T2DM and provide theoretical basis for clinical rational use of drugs.

Methods: We did a systematic review and meta-analysis of randomized, placbo-controlled clinical studies in patients with type 2 diabetes. We searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP database through October 2018, we also manually screened list of references to the previous meta-analysis of dapagliflozin in the treatment of type 2 diabetes. Data search and extraction were completed with a standardized data form and any discrepancies were resolved by consensus. A meta-analysis was conducted by using RevMan 5.3 software.

Results: Six randomized controlled trials (RCTs) including 2033 patients were analyzed. Compared with placebo, dapagliflozin monotherapy was associated with a reduction in glycosylated hemoglobin A1c (HbA1c) (weighted mean difference [WMD]: -0.60%; 95% confidence interval [CI]: -0.67%, -0.52%; P < .00001), fasting plasam glucose (FPG) (WMD: -1.30 mmol/L; 95% CI: -1.52, -1.08; P < .00001), and body weight (WMD: -1.50 kg; 95% CI: -1.67, -1.32; P < .00001). Dapagliflozin was associated with an increased risk of urinary tract infections (relative risk [RR]: 1.74; 95% CI: 1.21, 2.49; P = .003) and genital tract infections (RR: 3.52; 95% CI: 2.06, 6.03; P < .00001).

Conclusions: Dapagliflozin monotherapy was well tolerated and effective in reducing the level of HbA1c, FPG, and body weight in patients with T2DM without increasing hypoglycaemia, although it may increase the risk of urinary tract infections and genital tract infections. This meta-analysis provides an evidence for the treatment in patients with T2DM. However, more randomized clinical evidences are still needed to verify the results.

Citing Articles

Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.

Basu A, Montano-Campos F, Huang E, Laiteerapong N, Barthold D Diabetes Obes Metab. 2024; 26(11):5261-5271.

PMID: 39223846 PMC: 11479577. DOI: 10.1111/dom.15878.

Efficacy and safety of luseogliflozin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Galigutta R, Hasik P, Thomas C, Undela K Endocrine. 2024; 86(2):620-630.

PMID: 38884927 DOI: 10.1007/s12020-024-03925-x.

Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice.

Han Y, Li Y, Ye C, Gu Y, Chen X, Gu Q Exp Ther Med. 2024; 27(4):173.

PMID: 38476895 PMC: 10928832. DOI: 10.3892/etm.2024.12461.

A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE).

Guo L, Wang J, Li L, Yuan L, Chen S, Wang H BMC Med. 2023; 21(1):212.

PMID: 37316847 PMC: 10268430. DOI: 10.1186/s12916-023-02906-7.

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure.

Kurczynski D, Hudzik B, Jagosz M, Zabierowski J, Nowak J, Tomasik A J Cardiovasc Dev Dis. 2022; 9(7).

PMID: 35877587 PMC: 9325125. DOI: 10.3390/jcdd9070225.

References

Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E . Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig. 2016; 7(4):555-64. PMC: 4931206. DOI: 10.1111/jdi.12453. View

Reilly T, Graziano M, Janovitz E, Dorr T, Fairchild C, Lee F . Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014; 5(1):73-96. PMC: 4065287. DOI: 10.1007/s13300-014-0053-3. View

Gilor C, Niessen S, Furrow E, DiBartola S . What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters. J Vet Intern Med. 2016; 30(4):927-40. PMC: 5108445. DOI: 10.1111/jvim.14357. View

Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J . Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014; 16(11):1102-10. DOI: 10.1111/dom.12325. View

Ferrannini E, Ramos S, Salsali A, Tang W, List J . Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010; 33(10):2217-24. PMC: 2945163. DOI: 10.2337/dc10-0612. View

Weber M, Mansfield T, Cain V, Iqbal N, Parikh S, Ptaszynska A . Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2015; 4(3):211-220. DOI: 10.1016/S2213-8587(15)00417-9. View

Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-281. DOI: 10.1016/j.diabres.2018.02.023. View

Hayward R, Reaven P, Wiitala W, Bahn G, Reda D, Ge L . Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 372(23):2197-206. DOI: 10.1056/NEJMoa1414266. View

Prentki M, Nolan C . Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006; 116(7):1802-12. PMC: 1483155. DOI: 10.1172/JCI29103. View

10.

Lipska K, Yao X, Herrin J, McCoy R, Ross J, Steinman M . Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. Diabetes Care. 2016; 40(4):468-475. PMC: 5360291. DOI: 10.2337/dc16-0985. View

11.

Vallon V, Thomson S . Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2016; 60(2):215-225. PMC: 5884445. DOI: 10.1007/s00125-016-4157-3. View

12.

Vallon V, Platt K, Cunard R, Schroth J, Whaley J, Thomson S . SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2010; 22(1):104-12. PMC: 3014039. DOI: 10.1681/ASN.2010030246. View

13.

Vallon V . Molecular determinants of renal glucose reabsorption. Focus on "Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2". Am J Physiol Cell Physiol. 2010; 300(1):C6-8. PMC: 3023181. DOI: 10.1152/ajpcell.00444.2010. View

14.

Muller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E . Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018; 20(11):2598-2607. PMC: 6220756. DOI: 10.1111/dom.13437. View

15.

Bailey C, Iqbal N, Tjoen C, List J . Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012; 14(10):951-9. DOI: 10.1111/j.1463-1326.2012.01659.x. View

16.

Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell D . Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2013; 306(2):F188-93. PMC: 3920019. DOI: 10.1152/ajprenal.00518.2013. View

17.

Ji L, Ma J, Li H, Mansfield T, Tjoen C, Iqbal N . Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36(1):84-100.e9. DOI: 10.1016/j.clinthera.2013.11.002. View

18.

Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T . Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014; 5(2):415-33. PMC: 4269643. DOI: 10.1007/s13300-014-0086-7. View

19.

Gerich J . Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010; 27(2):136-42. PMC: 4232006. DOI: 10.1111/j.1464-5491.2009.02894.x. View

20.

Zhang M, Zhang L, Wu B, Song H, An Z, Li S . Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2013; 30(3):204-21. DOI: 10.1002/dmrr.2479. View